

## Transgene receives \$15.3 Million from the Sale of Securities Held for Sale

Strasbourg, France, July 17, 2023, 5:45 p.m. CET – **Transgene (Euronext Paris: TNG)**, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced **that it has received \$15.3 million (€ 14.0 million) as a result of the full disposal of its minority stake in a Chinese biopharmaceutical company.**

Following this transaction, which completion was expected for mid-2023, Transgene reaffirms its financial visibility until early 2024.

\*\*\*

### Contacts

**Transgene:**  
**Lucie Larguier**  
Director Corporate Communications & IR  
+33 (0)3 88 27 91 04  
[investorrelations@transgene.fr](mailto:investorrelations@transgene.fr)

**Media: MEDiSTRAVA Consulting**  
**David Dible/Sylvie Berrebi**  
+44 (0)203 928 6900  
[transgene@medistrava.com](mailto:transgene@medistrava.com)

### About Transgene

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.

The Company's clinical-stage programs consist of a portfolio of therapeutic vaccines and oncolytic viruses: TG4050, the first individualized therapeutic vaccine based on the *myvac*<sup>®</sup> platform, TG4001 for the treatment of HPV-positive cancers, as well as TG6002, BT-001 and TG6050, three oncolytic viruses based on the Invir.IO<sup>®</sup> viral backbone. With Transgene's *myvac*<sup>®</sup> platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. The *myvac*<sup>®</sup> approach allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by Artificial Intelligence capabilities provided by its partner NEC.

With its proprietary platform Invir.IO<sup>®</sup>, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.

Additional information about Transgene is available at: [www.transgene.fr](http://www.transgene.fr)  
Follow us on social media: Twitter: [@TransgeneSA](https://twitter.com/TransgeneSA) – LinkedIn: [@Transgene](https://www.linkedin.com/company/transgene)

.../...



### **Disclaimer**

*This press release contains forward-looking statements, which are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. The occurrence of any of these risks could have a significant negative outcome for the Company's activities, perspectives, financial situation, results, regulatory authorities' agreement with development phases, and development. The Company's ability to commercialize its products depends on but is not limited to the following factors: positive pre-clinical data may not be predictive of human clinical results, the success of clinical studies, the ability to obtain financing and/or partnerships for product manufacturing, development and commercialization, and marketing approval by government regulatory authorities. For a discussion of risks and uncertainties which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the Universal Registration Document, available on the AMF website (<http://www.amf-france.org>) or on Transgene's website ([www.transgene.fr](http://www.transgene.fr)). Forward-looking statements speak only as of the date on which they are made, and Transgene undertakes no obligation to update these forward-looking statements, even if new information becomes available in the future.*